Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

The Lancet Oncology

Volumn 19, Issue 3, 2018, Pages 347-355

  Giaccone, Giuseppe ^a   Kim, Chul ^a   Thompson, Jillian ^a   McGuire, Colleen ^a   Kallakury, Bhaskar ^a   Chahine, Joeffrey J ^a   Manning, Maria ^a   Mogg, Robin ^b   Blumenschein, Wendy M ^b   Tan, Ming T ^a   Subramaniam, Deepa S ^a   Liu, Stephen V ^a   Kaplan, Ian M ^c   McCutcheon, Justine N ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ADAPTIVE BIOTECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; DNA; GAMMA INTERFERON; LIVER ENZYME; METHYLPREDNISOLONE; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; RNA; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOTOXICITY; MALE; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POLYMYOSITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; THYMUS CANCER; TREATMENT DURATION; WASHINGTON; CLINICAL TRIAL; DISTRICT OF COLUMBIA; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; THYMOMA; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DISTRICT OF COLUMBIA; FEMALE; HUMANS; MALE; MIDDLE AGED; THYMOMA; THYMUS NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85041583128     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30062-7     Document Type: Article

References (31)

1. Engels, EA, Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5:10 suppl 4 (2010), S260–S265.
2. Ruffini, E, Detterbeck, F, Van Raemdonck, D, et al. Thymic carcinoma: a cohort study of patients from the European Society of Thoracic Surgeons database. J Thorac Oncol 9 (2014), 541–548.
3. Kelly, RJ, Petrini, I, Rajan, A, Wang, Y, Giaccone, G, Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 29 (2011), 4820–4827.
4. Thomas, A, Rajan, A, Berman, A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16 (2015), 177–186.
5. Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
6. Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
7. Weissferdt, A, Fujimoto, J, Kalhor, N, et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol 30 (2017), 826–833.
8. Padda, SK, Riess, JW, Schwartz, EJ, et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol 10 (2015), 500–508.
9. Reck, M, Rodríguez-Abreu, D, Robinson, AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
10. Fehrenbacher, L, Spira, A, Ballinger, M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
11. Keir, ME, Butte, MJ, Freeman, GJ, Sharpe, AH, PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
12. Rosai, J, Histological typing of tumours of the thymus. 2nd edn., 1999, Springer, New York.
13. Masaoka, A, Monden, Y, Nakahara, K, Tanioka, T, Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981), 2485–2492.
14. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
15. US Department of Health and Human Services National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf, May 28, 2009 (accessed July 1, 2017).
16. Petrini, I, Meltzer, PS, Kim, IK, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 46 (2014), 844–849.
17. Ayers, M, Lunceford, J, Nebozhyn, M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127 (2017), 2930–2940.
18. Johnson, DB, Balko, JM, Compton, ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
19. Heinzerling, L, Ott, P, Hodi, FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 4, 2016, 50.
20. Suster, S, Moran, CA, Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases. Am J Surg Pathol 20 (1996), 1469–1480.
21. Kuo, TT, Chan, JK, Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile. Am J Surg Pathol 22 (1998), 1474–1481.
22. Rajan, A, Heery, C, Mammen, A, et al. Safety and clinical activity of avelumab (MSB0010718C; anti-PD-L1) in patients with advanced thymic epithelial tumors (TETs). J Thorac Oncol 12 (2017), S314–S315.
23. Cho, J, Ahn, MJ, Yoo, KH, et al. A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor. J Clin Oncol, 35(suppl 15), 2017, 8521.
24. Burbelo, PD, Browne, SK, Sampaio, EP, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 116 (2010), 4848–4858.
25. Liu, Y, Zhang, H, Zhang, P, et al. Autoimmune regulator expression in thymomas with or without autoimmune disease. Immunol Lett 161 (2014), 50–56.
26. Radovich, M, Pickering, C, Felau, I, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell, 2018 (in press).
27. Thomas, A, Rajan, A, Berman, A, Giaccone, G, Multiorgan autoimmune manifestations associated with thymoma. J Thorac Oncol 10 (2015), e5–e7.
28. Rizvi, NA, Hellmann, MD, Snyder, A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
29. Le, DT, Durham, JN, Smith, KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
30. Wang, Y, Thomas, A, Lau, C, et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep, 4, 2014, 7336.
31. Rajan, N, Ashworth, A, Inherited cylindromas: lessons from a rare tumour. Lancet Oncol 16 (2015), e460–e469.